The earnings report is a clinical-stage biotech update with no revenue; the key catalyst is NS002's pivotal trial initiation in Q4 2026 and topline data in Q1 2027. Traders should monitor regulatory alignment announcements and any partnership or financing news ahead of the trial start. The CEO appointment adds execution risk/opportunity.
Price Chart
Executive Summary
Nasus Pharma reported a net loss of $5.9M for H1 2026, widening from $1.3M in H1 2025, driven by increased R&D and G&A costs as it advances NS002 toward a pivotal trial in Q4 2026. The company has $11.9M in cash, sufficient through Q2 2027, and appointed a new CEO. The stock is likely to move on pipeline milestones rather than financial results.
Key Financial Metrics
Key Facts
- Net loss of $5.9M for six months ended June 30, 2026, vs $1.3M loss in same period 2025
- Cash, cash equivalents and short-term deposits of $11.9M as of June 30, 2026, up from $4.3M at Dec 31, 2025
- R&D expenses increased to $2.6M from $0.3M, driven by NS002 development
- Appointed Brendan O'Grady as CEO effective July 27, 2026
- NS002 Phase 2 results showed statistically significant improvements vs EpiPen; pivotal study on track for Q4 2026 initiation with topline data expected Q1 2027
- NS003 preclinical PK study positive; first-in-human study expected in coming weeks
- Private placement raised ~$15.0M gross proceeds
Financial Impact
Net loss widened by $4.6M YoY; cash position strengthened by $7.6M via private placement
Risk Factors
- Clinical trial failure or delay for NS002 or NS003
- Cash runway only through Q2 2027; may require additional financing
- No revenue; fully dependent on pipeline success
- Dilution risk from warrants issued in private placement
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3346073 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 8, 2026 18d ago | 6-K | $3.51 | awaiting T+20 | — | $3.49 (−0.57%) |
Sep 23, 2026 4w ago | 3 | $3.64 $3.06 | ▼ −15.93% | ▼ −16.62% | $3.49 (−4.12%) |
Sep 18, 2026 5w ago | 424B5 | $3.44 $3.21 | ▲ +6.83% | ▲ +5.92% | $3.49 (−1.45%) |
Sep 14, 2026 6w ago | 6-K | $3.65 $3.32 | ▼ −9.04% | ▼ −11.30% | $3.49 (−4.38%) |
Sep 14, 2026 6w ago | EFFECT | $3.65 $3.32 | ▼ −9.04% | ▼ −11.30% | $3.49 (−4.38%) |
Aug 21, 2026 9w ago | EFFECT | $4.00 $3.44 | ▼ −14.00% | ▼ −13.47% | $3.49 (−12.75%) |
Aug 19, 2026 9w ago | 6-K | $3.84 $3.53 | ▼ −8.07% | ▼ −6.12% | $3.49 (−9.11%) |
Aug 17, 2026 10w ago | 6-K | $3.70 $3.59 | ▼ −2.97% | ▼ −1.00% | $3.49 (−5.68%) |
Aug 17, 2026 10w ago | Press Release | $3.70 $3.59 | ▼ −2.97% | ▼ −1.00% | $3.49 (−5.68%) |
Apr 1, 2026 29w ago | EFFECT | $2.55 $2.56 | ▼ −0.39% | ▲ +9.33% | $3.49 (−36.86%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers